Cellply vs En Carta Diagnostics
Cellply vs En Carta Diagnostics, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Cellply is on 52/100 and En Carta Diagnostics on 52/100.
Where each one leads
Cellply
- headcount: 25 against 12
- funding raised: $7.2M against $5.0M
- LinkedIn following: 9,134 against 2,091
En Carta Diagnostics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | Cellply | En Carta Diagnostics |
|---|---|---|
| What it is | DeepTech startup developing analytical tools for characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics. | Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity. |
| Category | Biotechnology, HealthTech, Artificial Intelligence, Medical Devices | Biotechnology, HealthTech, Diagnostics, Medical Devices |
| Sells toBusiness model | B2B | B2B2C |
| Offering | Hardware | Hardware |
| Founded | 2013 | 2022 |
| Headquarters | Bologna, Italy | Paris, France |
| Status | Active | Inactive |
Size, funding and growth
| Measure | Cellply | En Carta Diagnostics |
|---|---|---|
| Employees | 25 | 12 |
| Total funding | $7.2M | $5.0M |
| Latest round | Funding Round | Seed |
| LinkedIn followers | 9,134 | 2,091 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Cellply | En Carta Diagnostics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 52/100 | 52/100 |
| Traction | 48/100 | 45/100 |
| Team | 60/100 | 70/100 |
| Community | 15/100 | Not published |
| Search visibility | 33/100 | 20/100 |
| Quality | 58/100 | 58/100 |
| Domain ratingLink authority, 0-100 | Not published | 0/100 |
Cellply vs En Carta Diagnostics: common questions
Which is better, Cellply or En Carta Diagnostics?
Both score the same on our 0-100 rating, so the choice comes down to the 16 data points in the tables above rather than overall company strength.
How do Cellply and En Carta Diagnostics compare on the numbers?
Cellply leads on headcount (25 against 12), funding raised ($7.2M against $5.0M), LinkedIn following (9,134 against 2,091).
Read the full Cellply review and pricing or the En Carta Diagnostics review and pricing. You can also browse other Cellply alternatives we track.